Genmab — Maj 2020
-
Genmab Announces U.S. FDA Approval of Subcutaneous Formulation of Daratumumab, DARZALEX FASPRO
(daratumumab and hyaluronidase-fihj), for the Treatment of Patients with Multiple Myeloma
Company AnnouncementSubcutaneous formulation of daratumumab, DARZALEX FASPRO
, approved by the U.S. FDA for the treatment of patients with multiple myeloma
Approval based on data from Phase III COLUMBA and Phase II PLEIADES studies
In the studies, the fixed-dose subcutaneous formulation reduced treatment time -
skøn fredag. Men lidt som ventet ikke den store reaktion da det netop vr ventet. Læser jeg det rigtigt at det så ikke er 1. line
-
-
Trolmanden: 1 linie er med
Fedt med den nyhed en fredag aften. Cheers to that!
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind